

FILE 'HOME' ENTERED AT 10:00:34 ON 21 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.05

1.05

FILE 'REGISTRY' ENTERED AT 10:03:33 ON 21 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 DEC 2006 HIGHEST RN 916134-56-0

DICTIONARY FILE UPDATES: 20 DEC 2006 HIGHEST RN 916134-56-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "GALANTAMINE"/CN 25

E1	1	GALANTAMIN/CN
E2	1	GALANTAMINA/CN
E3	1 -->	GALANTAMINE/CN
E4	1	GALANTAMINE HYDROBROMIDE/CN
E5	1	GALANTAMINE HYDROCHLORIDE/CN
E6	1	GALANTASE/CN
E7	1	GALANTHAMIN-14-OIC ACID, 3-DEOXY-1,2-DIHYDRO-3-OXO-, ETHYL
E8	1	GALANTHAMIN-14-OIC ACID, 06-DEMETHYL-3-DEOXY-1,2-DIHYDRO-3-OXO-,
E9	1	ETHYL ESTER, (+)-/CN
E10	1	GALANTHAMINE/CN
E11	1	GALANTHAMINE (+)-DI-O-P-TOLUOYL-D-TARTRATE (2:1)/CN
E12	1	GALANTHAMINE A-NAPHTHYLCARBAMATE/CN
E13	1	GALANTHAMINE B-N-OXIDE/CN
E14	1	GALANTHAMINE 2-O-HEMISUCCINATE/CN
E15	1	GALANTHAMINE BUTYLCARBAMATE/CN
E16	1	GALANTHAMINE CARBONATE/CN
E17	1	GALANTHAMINE CHLOROAMYLATE/CN
E18	1	GALANTHAMINE ETHIODIDE/CN
E19	1	GALANTHAMINE ETHOXYHYDROXIDE/CN
E20	1	GALANTHAMINE HYDROBROMIDE-SYDNOCARB MIXT./CN
E21	1	GALANTHAMINE HYDROGEN BROMIDE/CN
E22	1	GALANTHAMINE HYDROXYMETHYLATE/CN
E23	1	GALANTHAMINE IODOAMYLATE/CN
E24	1	GALANTHAMINE IODOBUTYLATE/CN
E25	1	GALANTHAMINE IODOETHYLATE/CN
	1	GALANTHAMINE IODOISOPROPYLATE/CN

=> S E3

L1 1 GALANTAMINE/CN

=> DIS L1 1 IDE

THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 357-70-0 REGISTRY

ED Entered STN: 16 Nov 1984

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl- (7CI)

CN Galanthamine (6CI, 8CI)

OTHER NAMES:

CN (-)-Galantamine

CN (-)-Galanthamine

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, [4aS-(4a α ,6 β ,8aR*)]-

BRN 0093736

CN Galantamin

CN Galantamina

CN Galantamine

CN Jilkon

CN Lycoremin

CN Lycoremine

CN NSC 100058

CN [4aS-(4a α ,6 β ,8aR*)]-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol

FS STEREOSEARCH

DR 736-79-8, 1551-02-6


MF C17 H21 N O3

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NAPRALERT, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

997 REFERENCES IN FILE CA (1907 TO DATE)

45 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1004 REFERENCES IN FILE CAPLUS (1907 TO DATE)

27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> E "GALANTAMINE"/CN 25

E1	1	GALANTAMIN/CN
E2	1	GALANTAMINA/CN
E3	1 -->	GALANTAMINE/CN
E4	1	GALANTAMINE HYDROBROMIDE/CN
E5	1	GALANTAMINE HYDROCHLORIDE/CN
E6	1	GALANTASE/CN
E7	1	GALANTHAMIN-14-OIC ACID, 3-DEOXY-1,2-DIHYDRO-3-OXO-, ETHYL
ESTER, (±) -/CN		
E8	1	GALANTHAMIN-14-OIC ACID, O6-DEMETHYL-3-DEOXY-1,2-DIHYDRO-3-OXO-,
ETHYL ESTER, (±) -/CN		
E9	1	GALANTHAMINE/CN
E10	1	GALANTHAMINE (+) -DI-O-P-TOLUOYL-D-TARTRATE (2:1)/CN
E11	1	GALANTHAMINE A-NAPHTHYLCARBAMATE/CN
E12	1	GALANTHAMINE B-N-OXIDE/CN
E13	1	GALANTHAMINE 2-O-HEMISUCCINATE/CN
E14	1	GALANTHAMINE BUTYLCARBAMATE/CN
E15	1	GALANTHAMINE CARBONATE/CN
E16	1	GALANTHAMINE CHLOROAMYLATE/CN
E17	1	GALANTHAMINE ETHIODIDE/CN
E18	1	GALANTHAMINE ETHOXYHYDROXIDE/CN
E19	1	GALANTHAMINE HYDROBROMIDE-SYDNOCARB MIXT./CN
E20	1	GALANTHAMINE HYDROGEN BROMIDE/CN
E21	1	GALANTHAMINE HYDROXYMETHYLATE/CN
E22	1	GALANTHAMINE IODOAMYLATE/CN
E23	1	GALANTHAMINE IODOBUTYLATE/CN
E24	1	GALANTHAMINE IODOETHYLATE/CN
E25	1	GALANTHAMINE IODOISOPROPYLATE/CN

=> E "LYCORAMINE"/CN 25

E1	1	LYCOPUS EUROPAEUS, EXT./CN
E2	1	LYCOPUS VIRGINICUS, EXT./CN
E3	1 -->	LYCORAMINE/CN
E4	1	LYCORAMINE ACETATE/CN
E5	1	LYCORAMINE CARBONATE/CN
E6	1	LYCORAMINE HEXACHLOROPLATINATE (2-) /CN
E7	1	LYCORAMINE HYDROBROMIDE/CN
E8	1	LYCORAMINE HYDROCHLORIDE/CN
E9	1	LYCORAMINE METHINE/CN
E10	1	LYCORAMINE METHIODIDE/CN
E11	1	LYCORAMINE METHYLIODIDE/CN
E12	1	LYCORAMINE N-OXIDE/CN
E13	1	LYCORAMINE PERCHLORATE/CN
E14	1	LYCORAMINE PERCHLORATE (SALT) /CN
E15	1	LYCORAMINE PLATINICHLORIDE/CN
E16	1	LYCORAMINE, (±) -/CN
E17	1	LYCORAMINE, 2-DEOXY-2,8-DIOXO-/CN
E18	1	LYCORAMINE, 2-DEOXY-2,8-DIOXO-, (±) -/CN
E19	1	LYCORAMINE, 2-DEOXY-2-OXO-/CN
E20	1	LYCORAMINE, 2-DEOXY-2-OXO-, (±) -/CN
E21	1	LYCORAMINE, 7-DEMETHYL-8-OXO-, ACETATE (ESTER)/CN
E22	1	LYCORAMINE, 8-OXO-/CN
E23	1	LYCORAMINE, 8-OXO-, (±) -/CN
E24	1	LYCORAMINE, 8-OXO-, ACETATE (ESTER)/CN
E25	1	LYCORAMINE, 8-OXO-, ACETATE (ESTER), (±) -/CN

=> S E3


L2 1 LYCORAMINE/CN

=> DIS L2 1 IDE

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 21133-52-8 REGISTRY

ED Entered STN: 16 Nov 1984
 CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,7,8,9,10,11,12-octahydro-3-methoxy-11-methyl-, (4aS,6S,8aS)-(9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Galanthamine, 1,2-dihydro-
 CN Galanthamine, dihydro- (6CI)
 CN Lycoramine (7CI, 8CI)
 OTHER NAMES:
 CN 1,2-Dihydrogalanthamine
 CN Dihydrogalanthamine
 FS STEREOSEARCH
 DR 468-48-4, 1359-29-1
 MF C17 H23 N O3
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, EMBASE, MRCK*, NAPRALERT, SPECINFO, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

74 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 74 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
15.08	16.13

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:05:44 ON 21 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 20 Dec 2006 (20061220/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s galantamine or lycoramine or 21133-52-8 or 357-70-0

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L4 1004 L3

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6 74 L5

469 GALANTAMINE

105 LYCORAMINE

3 LYCORAMINES

105 LYCORAMINE

(LYCORAMINE OR LYCORAMINES)

L7 1182 GALANTAMINE OR LYCORAMINE OR L6 OR L4

=> s cogniti? or memory

23697 COGNITI?

136532 MEMORY

5864 MEMORIES

138253 MEMORY

(MEMORY OR MEMORIES)

L8 154652 COGNITI? OR MEMORY

=> s l7 and l8

L9 283 L7 AND L8

=> s cholesterol or hypercholesteremia or hyperlipidemia

169090 CHOLESTEROL

810 CHOLESTEROLS

169258 CHOLESTEROL

(CHOLESTEROL OR CHOLESTEROLS)

854 HYPERCHOLESTEREMIA

2 HYPERCHOLESTEREMIAS
856 HYPERCHOLESTEREMIA
(HYPERCHOLESTEREMIA OR HYPERCHOLESTEREMIAS)
11932 HYPERLIPIDEMIA
315 HYPERLIPIDEMIAS
12027 HYPERLIPIDEMIA
(HYPERLIPIDEMIA OR HYPERLIPIDEMIAS)

L10 175955 CHOLESTEROL OR HYPERCHOLESTEREMIA OR HYPERLIPIDEMIA

=> s l9 and l10

L11 5 L9 AND L10

=> d ti au abs so py 1-5

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment

AU Erkinjuntti, Timo; Roman, Gustavo; Gauthier, Serge; Feldman, Howard; Rockwood, Kenneth; Fisher, Marc

AB A review. Background- Cerebrovascular disease (CVD) and ischemic brain injury secondary to cardiovascular disease are common causes of dementia and cognitive decline in the elderly. CVD also contributes to cognitive loss in Alzheimer disease (AD). Summary- Progress in understanding vascular cognitive impairment (VCI) and vascular dementia (VaD) has resulted in promising symptomatic and preventive treatments. Cholinergic deficits in VaD due to ischemia of basal forebrain nuclei and cholinergic pathways can be treated with cholinesterase inhibitors used in AD. Controlled clin. trials with donepezil and galantamine in patients with VaD, as well as in patients with AD plus CVD, have demonstrated improvement in cognition, behavior, and activities of daily living. The N-methyl-d-aspartate receptor antagonist memantine stabilized progression of VaD compared with placebo. Primary and secondary stroke prevention, in particular with control of hypertension and hyperlipidemia, can decrease VaD incidence. Conclusions- From a public health viewpoint, recognition of VCI before the development of dementia and correction of vascular burden on the brain may lead to a global decrease of incident dementia.

SO Stroke (2004), 35(4), 1010-1017

CODEN: SJCCA7; ISSN: 0039-2499

PY 2004

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Compositions and methods for treating or preventing memory impairment

IN Cantillon, Marc

AB The present invention relates to pharmaceutical compns. for treatment or prevention of memory impairment which comprise a cholinesterase inhibitor and at least one other pharmacol. active agent selected from HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, gamma or beta secretase inhibitors, NMDA antagonists, muscarinic receptor agonists and nicotinic receptor agonists. Addnl., the present invention relates to the use of these pharmaceutical compns. to treat or prevent memory impairment in a mammal, such as a human.

SO U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO

PY 2004

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Administration of acetylcholinesterase inhibitors via intranasal delivery to the cerebral spinal fluid for treatment of cognitive disorders

IN Quay, Steven C.

AB Methods and compns. are disclosed that provide acetylcholinesterase

inhibitors for the prevention and treatment of diseases and disorders of the central nervous system, including dementia such as Alzheimer's disease, to the central nervous system via intranasal delivery. The methods and compns. of the present invention provide therapeutic concns. of the acetylcholinesterase inhibitor in the cerebrospinal fluid of a mammal without the attendant disadvantages, risks and side effects of oral or injection delivery.

SO U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO

PY 2003

2004

2004

2004

2004

2005

2005

2006

2004

2006

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Treatment of Alzheimer's disease: current status and new perspectives

AU Scarpini, Elio; Scheltens, Philip; Feldman, Howard

AB A review. Alzheimer's disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. Pharmacol. treatment of AD is based on the use of acetylcholinesterase inhibitors, which have beneficial effects on cognitive, functional, and behavioral symptoms of the disease, but their role in AD pathogenesis is unknown. Other pharmacol. therapies are becoming available-including the recently approved drug memantine, an NMDA channel blocker indicated for advanced AD. Here, we review clin. features of the available cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) including their pharmacol. properties, the evidence for switching from one agent to another, "head to head" studies, and the emerging evidence for the use of memantine in AD. New therapeutic approaches-including those more closely targeted to the pathogenesis of the disease-will also be reviewed. These potentially disease modifying treatments include amyloid- β -peptide vaccination, secretase inhibitors, cholesterol-lowering drugs, metal chelators, and anti-inflammatory agents.

SO Lancet Neurology (2003), 2(9), 539-547

CODEN: LNAEAM; ISSN: 1474-4422

PY 2003

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of modulators of nicotinic receptors for treatment of cognitive dysfunction

IN Davis, Bonnie M.

AB A method for treating the effects of low LDL-cholesterol values in the brain on cognitive performance or other central nervous system functions involves modulating nicotinic receptors by administering an effective amount of a nicotinic allosteric potentiator, an acetylcholinesterase inhibitor, nicotine, a nicotinic agonist or a mixture thereof to a patient in need of such modulation.

SO U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

PY 2003

2003

2003

2004

2003

2005

2005

```
=> s LDL-cholesterol or low(a)density(a)lipoprotein
    33874 LDL
    585 LDLS
    33956 LDL
        (LDL OR LDLS)
    169090 CHOLESTEROL
    810 CHOLESTEROLS
    169258 CHOLESTEROL
        (CHOLESTEROL OR CHOLESTEROLS)
    8352 LDL-CHOLESTEROL
        (LDL(W) CHOLESTEROL)
    2491489 LOW
    447 LOWS
    2491790 LOW
        (LOW OR LOWS)
    321132 DENSITY
    124712 DENSITIES
    417592 DENSITY
        (DENSITY OR DENSITIES)
    76039 LIPOPROTEIN
    83772 LIPOPROTEINS
    104430 LIPOPROTEIN
        (LIPOPROTEIN OR LIPOPROTEINS)
    21948 LOW(A) DENSITY(A) LIPOPROTEIN
L12 26879 LDL-CHOLESTEROL OR LOW(A) DENSITY(A) LIPOPROTEIN
```

```
=> d his
```

```
(FILE 'HOME' ENTERED AT 10:00:34 ON 21 DEC 2006)
```

```
FILE 'REGISTRY' ENTERED AT 10:03:33 ON 21 DEC 2006
```

```
    E "GALANTAMINE"/CN 25
L1 1 S E3
    E "GALANTAMINE"/CN 25
    E "LYCORAMINE"/CN 25
L2 1 S E3
```

```
FILE 'CAPLUS' ENTERED AT 10:05:44 ON 21 DEC 2006
```

```
S GALANTAMINE OR LYCORAMINE OR 21133-52-8/REG# OR 357-70-0/RE
```

```
FILE 'REGISTRY' ENTERED AT 10:06:11 ON 21 DEC 2006
```

```
L3 1 S 357-70-0/RN
```

```
FILE 'CAPLUS' ENTERED AT 10:06:11 ON 21 DEC 2006
```

```
L4 1004 S L3
```

```
FILE 'REGISTRY' ENTERED AT 10:06:12 ON 21 DEC 2006
```

```
L5 1 S 21133-52-8/RN
```

```
FILE 'CAPLUS' ENTERED AT 10:06:12 ON 21 DEC 2006
```

```
L6 74 S L5
L7 1182 S GALANTAMINE OR LYCORAMINE OR L6 OR L4
L8 154652 S COGNITI? OR MEMORY
L9 283 S L7 AND L8
L10 175955 S CHOLESTEROL OR HYPERCHOLESTEREMIA OR HYPERLIPIDEMIA
L11 5 S L9 AND L10
L12 26879 S LDL-CHOLESTEROL OR LOW(A) DENSITY(A) LIPOPROTEIN
```

```
=> s l7 and l12
```

```
L13 2 L7 AND L12
```

```
=> d ti au abs so py 1-2
```


L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Low-density lipoprotein receptor gene LDLR
 markers associated with age of onset of Alzheimer's disease
 IN Aerssens, Jeroen; Athanasiou, Maria; Brain, Carlos; Cohen, Nadine; Dain,
 Bradley; Denton, R. Rex; Judson, Richard S.; Ozdemir, Vural; Reed, Carol
 R.
 AB Haplotypes in the LDLR gene associated with age of onset of Alzheimer's
 disease (AD) are disclosed. This discovery is based on clin. and biochem.
 characterization of selected individuals in a cohort of 449 Caucasian
 patients diagnosed with AD, each of whom had previously participated in a
 clin. trial of galantamine. Fourteen polymorphic sites (in
 introns 1, 5, 10, 11, 14, and 17, and in exons 2, 8 and 12) and 764
 haplotypes are identified. Testing for the presence or absence, and copy
 number, of these haplotypes is useful for predicting the age at which
 individuals who are at increased risk for AD are likely to develop the
 disease and to help confirm a diagnosis of mild or minimal cognitive
 impairment (MCI) or AD. Individuals determined to have an age-of-onset
 haplotype I are predicted to develop AD between 71.9 and 81 years of age,
 and individuals with marker II are predicted to develop AD between 64.1
 and 71.3. In addition, the correlation of certain LDLR haplotypes with age
 of AD onset indicates that variation in the LDLR gene should be considered
 in the development and clin. trials of drugs for testing MCI, AD, and
 other neurodegenerative disorders. This correlation also provides a basis
 for pursuing LDLR as a target for drugs designed to treat such cognitive
 disorders. Allele-specific oligonucleotide probes and oligonucleotides
 for allele-specific primer extension are provided for haplotyping assays.
 SO PCT Int. Appl., 223 pp.
 CODEN: PIXXD2
 PY 2005
 2006
 2006

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Use of modulators of nicotinic receptors for treatment of cognitive
 dysfunction
 IN Davis, Bonnie M.
 AB A method for treating the effects of low LDL-cholesterol
 values in the brain on cognitive performance or other central nervous
 system functions involves modulating nicotinic receptors by administering
 an effective amount of a nicotinic allosteric potentiator, an
 acetylcholinesterase inhibitor, nicotine, a nicotinic agonist or a mixture
 thereof to a patient in need of such modulation.
 SO U.S. Pat. Appl. Publ., 6 pp.
 CODEN: USXXCO
 PY 2003
 2003
 2003
 2004
 2003
 2005
 2005

=>

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 21133-52-8 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,7,8,9,10,11,12-octahydro-3-methoxy-11-methyl-, (4aS,6S,8aS)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Galanthamine, 1,2-dihydro-
 CN Galanthamine, dihydro- (6CI)
 CN Lycoramine (7CI, 8CI)
 OTHER NAMES:
 CN 1,2-Dihydrogalanthamine
 CN Dihydrogalanthamine
 FS STEREOSEARCH
 DR 468-48-4, 1359-29-1
 MF C17 H23 N O3
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, EMBASE, MRCK*, NAPRALERT, SPECINFO, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

74 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 74 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 357-70-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl- (7CI)
 CN Galanthamine (6CI, 8CI)
 OTHER NAMES:
 CN (-)-Galantamine
 CN (-)-Galanthamine
 CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, [4aS-(4a α ,6 β ,8aR*)]-
 CN BRN 0093736
 CN Galantamin
 CN Galantamina
 CN Galantamine
 CN Jilkon
 CN Lycoremin
 CN Lycoremine
 CN NSC 100058
 CN [4aS-(4a α ,6 β ,8aR*)]-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol
 FS STEREOSEARCH
 DR 736-79-8, 1551-02-6
 MF C17 H21 N O3
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHM, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NAPRALERT, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

997 REFERENCES IN FILE CA (1907 TO DATE)
 45 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1004 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	520	galantamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/21 08:58
S2	76831	cholesterol	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/20 14:29
S3	161	S1 and S2	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/20 14:29
S4	22	S1 and S2 @py<="2003"	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/20 14:29
S5	32	lycoramine	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/21 08:59
S6	76944	cholesterol	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/21 08:59
S7	3	S5 and S6	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/21 09:02
S8	1957647	cogniti\$3 or memory	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/12/21 09:03
S9	546	galantamine or lycoramine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/12/21 09:03
S10	313	S8 and S9	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/21 09:03
S11	83915	hyperlipidemia or cholesterol or dyslipidemia	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/21 09:06

EAST Search History

S12	100	S10 and S11	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/12/21 09:07
-----	-----	-------------	---	-----	----	------------------